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ABSTRACT
OPTIMIZATION AND APPLICATION OF METABOLOMIC ASSAYS FOR
ANALYZING DIET-INDUCED AND GUT MICROBIOTA-DERIVED SHORTCHAIN FATTY ACIDS IN MICE AND HUMANS
ROBERT JUENEMANN
2016
Introduction: In recent decades, the obesity epidemic worldwide has prompted
the need for research targeting disease prevention, treatment, and maintenance. Dietary
interventions are one of the primary methods to instill positive nutrition habits into one’s
lifestyle. Thus, resistant starch type 4 (RS4), a prebiotic dietary fiber, has been proposed
to induce beneficial immunometabolic health outcomes. Currently there is a lack of
knowledge on the health outcomes of RS4 in adults with metabolic syndrome (MetS).
Goal: The goal of this research was to optimize a metabolomic assay to quantify fecal
short chain fatty acids (SCFAs), a byproduct of microbial fermentation in the gut, and to
apply this assay to health outcomes of RS4 intervention in an adult population with MetS
as well as genetically induced obese mice. Methods: An assay was optimized to extract
and derivatize fecal SCFA from human stool samples followed by quantification using
gas chromatography – mass spectrometry (GC-MS). Retrospective analysis of fecal
samples from adults including both men (n=4) and women (n=12) with signs of MetS,
collected at four time points throughout an ad libitum dietary intervention of RS42, were
processed and quantified. This method was also retrospectively applied to cecum samples
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of KK.Cg-Ay/a, genetically induced obese mouse model, to quantify the effects of RS4
on cecum SCFA concentrations. 16S rRNA sequencing was performed to study the effect
of RS4 on gut microbial composition. Blood biomarkers, glycemic, and lipid viariables,
anthropometric measurements, and diet nutrient composition were also studied. Results:
GC-MS analysis revealed significantly increased SCFAs following RS4 consumption
including butyrate, propionate, valerate, isovallerate, and hexanoate. 16S-rRNA gene
sequencing revealed a differential abundance of 71 bacterial operational taxonomic units,
including the enrichment of three Bacteroides species and one each of Parabacteroides,
Oscillospira, Blautia, Ruminococcus, Eubacterium, and Christensenella species in the
RS4 group. RS4-specific associations were found between gut microbial composition and
SCFA concentrations. Cholesterols, fasting glucose, glycosylated haemoglobin, and
proinflammatory markers in the blood as well as waist circumference and % body fat
were lower post intervention in the RS4 group compared with the control group. In
KK.Cg-Ay/a mice, butyrate was significantly enriched in RS4 fed mice intestinal tissue.
Discussion: An optimized method to quantify intestinal and fecal SCFA was created. The
biological function of RS4 on gut microbiota in inidividuals with MetS was also
identified. Larger studies are needed to fully understand the mechanistic action of RS4 in
individuals with metabolic dysfunction for future implications on dietary guidelines.
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CHAPTER 1. REVIEW OF LITERATURE
1.1

Nutrigenomics and Health
In recent years, technology has advanced allowing for the development of many

different, but related -omics technologies including genetics and disease/condition risk genomics, protein expression -proteomics, gene transcription -transcriptomics, and
metabolism -metabolomics. These –omics technologies in general are a consortium of
modalities used to investigate the roles, interations, and mechanisms of cells within an
organism. The creation of these new –omics technologies has led to a dramatic increase
in the amount of data available to study factors that influence disease susceptibility,
occurrence, progression and cessation. Dating back to the Greek physician Hippocrates,
the significant association between an individual’s diet and their health has been cited.
Bringing together past theories and current technological advancements, interest has
arisen between bioactive food componants BFCs and its relationship with ones genes.
Nutrigenomics was first mentioned in 2001 as the new frontier in the science of
nutrition3,4. The term Nutrigenetics was earlier described however, while similar, these
two disciplines are not interchangeable. Nutrigenomics is the science of how bioactive
food compounds effect gene expression through epigenetic modifications, miRNA and
RNA modifications, changes in protein expression and metabolite changes3,5.
Nutrigenetics is the study of genetic variation and dietary response in an individual or
population5-7. The main goals of these sciences include both personalized and
preventative nutrition4. The future of Nutrigenomics applied to real life has been an
exciting endeavor however; significant ethical debate around its current application
exists. A recent review by Pavlidis et al., 2015 outlined the current status of
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Nutrigenomics science and its future applications. Its applications on personalized
nutrition for a subset of responders vs. overall public health brings scrutiny to the overall
costs and rigor of the newly formed –omics sciences4. Bioactive food componants may
influence gene expression in a variety of mechanisms including via signal transduction
molecules, their metabolites, or directly6. It is widely known that individual’s respond
differently to dietary consumption, hence the interest in nutrigenomics. Humans are
predisposed to many different health conditions including obesity, cancers and
cardiovascular disease based off not only their genetics but also their environment. With
that being said BFCs may have either a positive or a negative effect on an individual’s
health. Moving forward, the complexity of this science requires a significant amount of
research to effectively be applied into today’s dietetic and healthcare settings.
1.2

Metabolic Syndrome
The rise in obesity in recent decades has quickly become one of the largest

burdens on healthcare globally8 as it may elevate the risk for development of more
serious conditions including diabetes mellitus, certain cancers and cardiovascular
disease9, the leading cause of mortality in the US10. Obesity in adults can be defined as
having a BMI at or above 30. In children and adolescents’, obesity is defined as a BMI at
or above the 95th percentile for their age range and gender. In 2011-2012 it was estimated
that more than one-third or 34.9% of adults were obese and two-thirds of adults were
overweight in the US11, similar to rates in 2003-2004, however the prevalence of obesity
has been predicted to rise in coming years12. Thompson et al., 2001 found that
overweight individuals (BMI 25-29) and obese individuals (BMI ≥30) had 37% and
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105% higher annual prescription costs and 13% and 39% higher primary care costs
compared to their health counter parts respectively13.
Abdominal obesity, presenting comorbid with some of the most dangerous risk
factors for developing a heart attack including hypertension, dyslipidemia and insulin
resistance encompass an even more serious condition, metabolic syndrome. Globally it is
estimated that 20-25% of the adult population has metabolic syndrome14. Between 20032012 in the United States it was estimated that 33% of the adult population and over 50%
of the population of over 60 years of age had metabolic syndrome causing concern with
the rapidly growing geriatric population in the US15. The International Diabetes
Federation (IDF) defines metabolic syndrome as follows in Table 1-1.

Table 1-1: The IDF Definition of Metabolic Syndrome
Criteria

Male

Female

Body Mass Index

>30 kg/m2

>30 kg/m2

Waist Circumference

>94 cm

>80 cm

Elevated Triglycerides

≥150 mg/dL

≥150 mg/dL

Reduced HDL Cholesterol
(HDL)

<40 mg/dL

<50 mg/dL

High Blood Pressure

Systolic > 130 mm Hg

Systolic > 130 mm Hg

I. Criteria A

II. Criteria B
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Elevated Fasting Plasma
Glucose

Diastolic >85 mm Hg

Diastolic >85 mm Hg

>100 mg/dL

>100 mg/dL

Table 1-1: Criteria used to define MetS based off the (IDF)14. An individual is
considered to have MetS if they present with one item from criteria A and any two
from criteria B above.
Obesity and metabolic syndrome are caused by several environmental, genetic,
dietary and lifestyle factors including but not limited to, sedentary lifestyle, higher energy
intake than output, insulin resistance and certain genetic predispositions. Metabolic
syndrome and its co-morbidities can be treated through lifestyle and/or dietary
interventions as well as other therapeutics including pharmaceuticals. Despite availability
of treatment and prevention options, the prevalence of MetS is rising worldwide at an
alarming rate10,14.
There are numerous treatment options for metabolic syndrome and its
comorbidities including medications, dietary interventions/changes, behavioral
modifications and exercise. A basic understanding of weight loss reflects the first law of
thermodynamics which says energy can neither be created nor destroyed; energy intake
may be neutral (expenditure=consumption), positive (expenditure<consumption), or
negative (expenditure>consumption). The most obvious influence of energy consumption
is food consumption, whereas there are three main categories of energy expenditure.
These categories are: exercise, adaptive thermogenesis and resting metabolic rates16. The
clearest and simplest way to increase energy expenditure is via increased exercise since
the latter are both mechanisms of survival. Both weight loss medications and reducing
energy intake are effective interventions in 5-9% weight loss, however weight typically
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plateaus after six months17. A significant struggle with weight loss is long-term success
and maintenance. Numerous publications identify initial success of weight loss is not
predictive of long-term success17,18. Summerbell et al., 2008 described low-energy and
low-fat consumption to inverse excess energy intake are not suitable interventions for
long-term weight loss19.
1.3

Resistant Starch
In recent decades, growing evidence has been produced supporting the influence

of diet on the etiology, prevention and treatment of many health conditions. Rapidly
digested starchy foods such as white pastas, white bread and cakes have long been known
to influence chronic diseases such as type-2 diabetes mellitus (T2DM) and obesity.
Normal dietary starch begins its digestion in the mouth as it is broken down by the
enzyme amylase where it travels further down into the digestive tract and is rapidly
absorbed as glucose which may potentially result in a hyperglycemic environment in the
blood. This hyperglycemic condition triggers the release of insulin which cascades into
tissue-specific intracellular uptake of glucose ultimately leaving a hypoglycemic
environment in the blood. This cascade of events may result in insulin resistance which
further may contribute to T2DM and ultimately more serious conditions such as
metabolic syndrome and cardiovascular disease.
To combat this rapid glycemic response growing evidence has supported the
addition of resistant starches (RS) into the diet for disease prevention, maintenance and
treatment20,21. Resistant starches are found both naturally in foods as well as
mechanically engineered and are classified based on the characteristics that render them
indigestible (Table 1-2)22. Resistant starch is capable of avoiding enzymatic digestion in
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the mouth and gastral systems however it is susceptible to microbial fermentation thereby
a slower, more modulated glucose response20. Also of interest, is the production of short
chain fatty acids (SCFA) in the lower gastrointestinal intestinal system (GI) through
fermentation.21 The ability of a RS to be digested by the microbes of our gut renders them
a prebiotic fiber. A prebiotic fiber is a non-digestible food component which selectively
serves as a substrate for beneficial microbial species which undergoes microbial
fermentation23. Resistant starch is a prebiotic friber as it selectively promotes growth of
beneficial microbes in the gut; however, not all fibers are considered prebiotics, cohersely
not all prebiotics are resistant starch. A probiotic on the other hand is the healthy,
commensal bacteria that occupy our gut which through research have contributed to
beneficial health outcomes23.
Table 1-2: Types of resistant starch20,22
Designation

Description

Example

Reference

RSI

Physically inaccessible

Coarsely ground or

Englyst et al.,

starch

whole-kernel grains

199222

Granular starch with the

High amylose maize

Englyst et al.,

B- or C- polymorph

starch, raw potato,

199222

RSII

raw banana

RSIII

Retrograded Starch

Cooked and cooled

Woo et al.,

starchy foods

200224
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RSIV

Chemically modified

Crosslinked starch

Han, BeMiller,

starch

and octenyl succinate

200725

starch

RSV

1.4

Amyloid-lipid complex

Stearic acid-

Seneviratne,

complexed high-

Biliaderis,

amylose starch

199126

Microbiome
The etiopathology of obesity and metabolic syndrome have been of interest

worldwide due to their complexity and rapidly increased occurrence. More recently, the
relationship between the microbiome and health has been of growing interest. The
microbiome encompasses all of the microbes that occupy our body space. It is estimated
that these microbes make up over ten times higher the number of cells in the body, with
the majority residing in the large intestine. The gut microbiome plays a crucial role in
nutritional sciences as it increases the metabolic potential of the human host thereby
digesting food components we would not otherwise be able to.
The composition of the gut microbiome is influenced by many factors including
age, diet, disease, medications and host genetics27,28. The gut microbiome is primarily
made up of six bacterial phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria,
Fusobacteria, and Verrucomicrobia. Though complex, research has produced common
trends associated with certain disease states including obesity, cancers and T2DM. Gut
microbiome plays a crucial role in interacting with our mucosal immune system. The
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interaction between the human host, gut microbiome and diet is complex as noted in
Figure 1-1. It has been found that microbial fermentation may increase energy production
from the diet, contribute to low-grade inflammation and influence fatty acid tissue
composition27. Despite the rapid increase of publications regarding the gut microbiome
and obesity, there is a significant variation in microbial composition from person to
person however, trends suggest a healthy and more disease-like state. A significant
number of studies describe an obese-like microbiome as having an increased Firmicutes:
Bacteriodetes ratio27,29,30.

Figure 1-1: Relationship of the gut microbiome, diet, and human host1.
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The addition of RS to the diet has been shown to have beneficial influences on the
gut microbiome and immunological functions in both mouse models and human
interventions. RS in the diet has been shown to increase the abundance of beneficial
microbes including Bifidobacterium adolescentis, Ruminococcus bromi, Eubacterium
rectale, and Parabacterium distasonis as well as improving the Firmicutes:
Bacteriodetes30,31. It is important to note that the results previously mentioned resulted
from the consumption of different types of RS concluding that microbial growth and
colonization are substrate dependent32.
1.5

Hutterite Brethren Population of South Dakota
South Dakota is home to a large population of Hutterites, one of the oldest and

most successful Anabaptist Brethren societies, the Hutterites. Their culture dates back to
1528 from South Tyrol, once part of Austria. Their population has endured significant
hardship however, their population has expanded to over 40,000 individuals across
Canada and the USA, primarily in the Midwestern states including North Dakota, South
Dakota and Canada33. Their communal lifestyle has led to a genetically isolated
population resulting in a founder effect resulting from the genetic flow from the original
89 community founders which can be associated to the Mendelian disorders present
within this community33,34. The inclusion of the Hutterite population in genetic studies
has increased significantly in recent decades positively impacting the ability to identify
specific genes related to disorders that are unique to this population. Their inclusion as a
study population provides a significant opportunity to avoid potential genetic factors due
to their genetic isolation.

10
In the context of nutrition and gut microbiome research, the Hutterites restrict the
potential environmental factors that may impact study results. Their communal lifestyle
within their colonies involves centralized preparation and consumption of their three
main meals. This communal dining limits the potential variation amongst their diet. A
major cause of variation is seasonal availability of fruits and vegetables (fresh fruits and
vegetables being available for consumption in summer and fall months, preserved,
canned, or frozen fruits and vegetables in winter and spring months). This seasonal
variability has lead to the microbial shifts across seasons including the abundance of
particular taxa including Firmicutes and Bacteroidetes as well as overall microbial
diversity35.
1.6

Intervention Study
In order to further understand the effects of RS4, Nichenametla et al., 2014

performed a double-blind, placebo-controlled, cluster crossover intervention in two
Eastern South Dakota Hutterite colonies2. The two Hutterite colonies (n=86) were
randomized to alternatively receive either the test flour or control flour (Table 1-3) in two
consecutive 12-week treatment periods with an appropriate two-week washout period
(control flour consumed) in between as shown in Figure 1-2. Preexisting colony flours
were removed and replaced with test flours which were fed ad libitum in a domestic, freeliving, communal environment. Participants in this study were ≥18 years old and
provided written informed consent to participate. Exclusion criteria for this study include
lactating or pregnant females, long-term antibiotic therapy, immune compromised, cancer
and other chronic conditions inhibiting one’s ability to provide informed consent and
abide by study protocol.
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Figure 1-2: Crossover design timeline of 26 week long study period. Flours
consumed in two 12 week treatment periods were randomized by colony following
initial baseline (BL). The two treatments were divided by a two week washout
period (WO) followed by consumption of the opposite treatment flour. Arrows
depict time of data and specimen collection.
Table 1-3: Nutrient composition of treatment flours
Nutrient (g/100g)

Control Flour

RS4 Flour

Water

13.4

12.5

Protein

11.0

7.9

Carbohydrates

73.5

77.8

Total fat

1.7

1.3

Saturated fat

0.2

0.2

Monounsaturated fat

0.1

0.1

12
.

Polyunsaturated fat

0.7

0.6

Trans-fat

0.0

0.0

Fiber (RS4)

2.4 (0.0)

25.7 (24.0)

Sugars

0.3

0.2

Ash

0.5

0.6

Calcium (mg/100g)

24.0

50.4

Sodium (mg/100g)

2.0

91.4

Vitamin C (mg/100g)

0.0

0.4

Calories (kcal)

361.0

266.8

The results of this study show that RS4 consumption improved dyslipidemia by
significantly decreasing mean total cholesterol, lower non-HDL cholesterol and HDL
cholesterol in individuals with metabolic syndrome. In conclusion the aims of this thesis
was to mechanistically explore the effects of RS4 on individuals with metabolic
syndrome and the gut microbiome.
Initially collaboration was sought out within various departments at SDSU to
investigate fecal SCFA however no optimized method was found. Protocols were found
for volatile fatty acids but of larger molecular structure and concentration. Due to the low
concentration of SCFAs anticipated in the potential samples, their high volatility, and low
molecular weights, these GC-MS machines were incapable of reaching the lower
detection limit desired. Outside collaboration was sought out to local laboratories.
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Outside collaboration attempts found high cost, inadequate amount of sample, and low
detection ranges. At this point the research need within SDSU for current and future
studies to optimize a method for SCFA extraction and analysis via GC-MS was
identified. Two professors within SDSU’s Pharmacy and Chemistry with GC-MS
capacity initially assisted with previously published protocol replication (outcomes of
protocol replication in section 2.4). Unfortunately, retirement, machine use, and lack of
laboratory assistance/support limited the success of these collaborations. Since recourses
at SDSU were exhausted, Dr. Dey sought out collaboration with Dr. Ali Reza Fardin-Kia
with this US Food and Drug Administration which ultimately lead to the successful
protocol developement.
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CHAPTER 2. OPTIMIZATION OF A METABOLOMIC ASSAY TO ANALYZE
SHORT CHAIN FATTY ACIDS IN HUMAN FECES
2.1

Introduction
Upon reaching the lower GI tract, prebiotic fibers such as RS, undergo microbial

fermentation which produces SCFAs. SCFAs of particular interest include acetate,
propionate, and butyrate which have numerous physiological impacts on the body such as
inducing satiety, hepatic lipogenesis, fat deposition, and thermogenesis36,37. Short-chain
fatty acid production directly correlates with the type of substrate in the diet and
microbial availability in the gut. The majority of SCFA produced are absorbed by the
intestinal epithelium and used in other metabolic processes or are used by other intestinal
microbiota. The study of the gut microbiota and fecal SCFA production is controversial
as only 5-10 % of SCFA produced are excreted in feces (the primary method of study)38
however this is the most practical method of SCFA study in clinical trials. It has been
estimated that SCFA production can account for 5-15% of daily human caloric intake39.
The molar ratio of SCFA is estimated 60:20:20, acetate, propionate and butyrate
respectively38,40.
Butyrate is of particular interest in research as it has been found to have many
effects on energy metabolism, inflammation, host immunity and cancer. There are two
proposed mechanisms of butyrate production 1) Butyrate kinase and 2) ButyrylCoA:acetate-CoA transferase41. Commonly cited butyrogenic bacteria include:
Eubacterium rectale, Eubacterium ramulus, Roseburia cecicola and members of
Clostridium cluster IV42. It is well known that butyrate is the main energy source for
colonocytes once absorbed. Inflammation is commonly associated with both obesity and

15
cancer. Butyrate plays a crucial role in inflammatory response in the gut by inhibiting
pro-inflammatory markers such as IL-6 and inhibiting NF-kBactivation as well as
upregulating PPARγ expression43,44.
Propionate and acetate play fundamental roles with the liver where they both may
be metabolized, acetate forming acetyl-CoA and contribute to gluconeogenesis.
Propionate has been shown to increase HDL cholesterol production in humans as well as
reduce blood cholesterol in animal models45. Acetate and propionate have also been
shown to play a role in adipocyte formation through interaction with G-protein coupled
receptors and also influence adipokine release which may induce satiety46. Acetate has
been noted to induce satiety signaling through hypothalamic reaction after
administration47.
Relating this to obesity and metabolic syndrome, the addition of RS to the diet
reduces the energy density by which intestinal gluconeogenesis is initiated and satiety is
induced through activation of these SCFA48. The complex relationship between the gut
microbiome, SCFA and obesity has yet to be fully understood. In today’s western diet the
amount of fiber in the diet is limited, drawing concern over health outcomes/trends,
especially the obesity epidemic. On average in the US the daily fiber intake is 16 grams
for individuals 2 and older49. The dietary reference intake for total fiber for adult male
and females is between 21-38 grams per day50. The addition of fiber into the diet has
been of growing interest for health organizations in recent decades due to the increasing
evidence of health promotion via SCFA production. While there is no recommended
dietary reference intake values for RS consumption in the US, it is estimated that the
average daily intake is 3-8 grams per day in the US51.
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The increased biological relevance of these compounds has increased the need to
develop rapid and accurate detection platforms. Detecting SCFA in fecal samples is
particularly difficult due to the complex matrices into which they reside52. There are
several pretreatment protocols available in which the SCFAs are extracted using an
aqueous or organic solvent and often times followed by a derivatization reaction to
increase the volatility and compatibility with the GC-MS analysis. In section 2.4 two
methods are described which were attempted one with a simple extraction and one with
an additional derivatization reaction.
The objectives of this project were 1) to develop and optimize a protocol to analyze
SCFA in human fecal samples and 2) to investigate the impact of RS4 on fecal short
chain fatty acid (SCFA) concentrations in adults with metabolic syndrome.
2.2
2.2.1

Materials and Methods
Participants

Participants in this study included a subset of the parent cohort (section 1.6)
consisting of 20 individuals who originally participated in a dietary intervention with
RS42. The parent trial is registered in clinicaltrials.gov (NCT01887964). From 40
participants who had signs of metabolic syndrome at baseline, 26 participants submitted
stool samples at all four data collection time points. Out of 26, 20 participants (10 from
each of the two colonies) were included in the current investigation as their fecal samples
were adequate to carry out both sequencing and short chain fatty acid (SCFA) analyses.
Exclusion criteria included pregnancy, lactation, long-term antibiotic therapy, immune
compromised state, cancer, and other conditions that would affect the ability to provide
informed consent or comply with the protocol.
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2.2.2

Sample preparation.

Performed at South Dakota State University, 1.5mg/mL internal standard (IS, 2ethylbutyric acid, Thermo Fisher Scientific, Waltham, MA) was prepared in 1-butanol
(Thermo Fisher Scientific, Waltham, MA). Exact weight of IS was recorded. 8001000mg (±0.1mg) fecal sample was homogenized and added to a 30mL glass tube with a
Teflon cap (Thermo Fisher Scientific, Waltham, MA) containing 1mL IS. 500µL hexane
(Thermo Fisher Scientific, Waltham, MA) and 2mL of the appropriate catalyst were then
added with one minute of vortexing between each addition. Boron trifluoride 1-butanol
(BF3-B, Sigma Aldrich, St. Louis, Missouri) and hydrogen chloride 1-butanol (HCl-B,
Sigma Aldrich, St. Louis, Missouri) were used to create butyl- esters for SCFA detection.
Boron trifluoride 1-methanol (BF3-M) was used to create methyl- esters for MCFA
detection. Samples were then sonicated for five minutes at 40 KHz, purged with nitrogen
or helium gas (Matheson, Sioux Falls, SD), and placed in a water bath (90-100oC) for 20
minutes. Once cooled to room temperature, 15mL of water and an additional 1.5mL of
hexane were added to the samples and centrifuged at 3,000g*min-1 for two minutes. The
organic layer (top) was then transferred into a sampling vial (Agilent Technologies,
Wilmington, DE) with a final addition of ~100mg anhydrous sodium sulfate (Thermo
Fisher Scientific, Waltham, MA). Fecal SCFA extracts were stored at -20oC. A
schematic view of the protocol is indicated in Figure 2-1.
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Figure 2-1: Optimization of a metabolomic assay to analyze SCFA in human feces.

2.2.3

Gas chromatography- mass spectrometry analysis.

Performed at the US Food and Drug Administration, (College Park, MD) fatty
acid analysis was executed using GC-MS 5977A (Agilent Technologies, Wilmington,
DE). Analytes were run on a HP-5MS UI capillary column (30 m x 0.25mm, 0.2 μm
thickness, Agilent, Wilmington, DE). Sample volume of 1µL was injected in the split
mode (1:10). The carrier gas in this system was hydrogen with a constant flow rate of
2mL/min. Oven temperature ramp was as follows: 55oC for 4 minutes, then to 120 oC at 5
oC

/min, then to 220 oC at 20 oC /min for 10 minutes. Selective mass detector was utilized

in the “single ion monitoring and scan” (SIM/Scan) mode with its source being
maintained at 150 oC and the electron energy set to 70eV. A schematic view of the GCMS protocol is shown in Figure 2-2.
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Figure 2-2: GC-MS method for SCFA analysis. 1. Hydrogen used as carrier gas at
1.9mL/min. 2. Injection volume 1uL in split mode (1:10). 3. Initial elution
temperature was 55oC for 4 min, then 5oC/min to 120oC and then 20oC/min to 220oC
for 10 min. 4. Mass detector operated in SIM/Scan mode. 5. Ion source 150oC. 6.
Electron energy 70eV.

2.2.4

Statistical analysis

Descriptive statistics were performed on demographic information. Data was
analyzed comparing end-points for outcome variables in CF and RS4 groups, or pre- and
post-intervention measures. For pre- and post-intervention comparisons paired t-test
(Wilcoxon signed-rank test for non-normal data) was used, while student’s t-test (MannWhitney signed-rank test for non-normal data) was used to compare the two different diet
groups. Where necessary, data was logarithmically transformed to achieve normality. A p
value of 0.05 or less was considered significant, while p value of 0.05 to 0.09 was
considered trend or approaching significance.
2.3

Results and discussion.
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Descriptive characteristics of this study cohort are summarized in Table 2-1. Of
the original cohort, at baseline, 40 individuals met the IDF definition of MetS14. 26
participants of these subjects submitted stool samples at all four visits. Out of these 26
individuals (ages 32-77), 20 had fecal microbial DNA at sufficient concentration for next
generation sequencing (NGS). These 20 individuals were from two colonies, ten from
each colony, two being men and eight being women. Medication for comorbid conditions
and prophylaxis are reported in Table 2-1 below.
Table 2-1: Baseline characteristics of 20 participants.
Criteria
Age (years)
<50
≥50

5
15

BMI
<30
≥30

5
15

Gender
Male
Female

8
12

Medication for
No medication
Type 2 diabetes
Heart diseases
Blood pressure
Fibre supplement
Probiotic
supplement
Digestive support
Cholesterol
lowering

n

8
4
2
11
2
1
3
5

n: number of individuals.53
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Figure 2-3: Representative chromatogram showing the overlay of retention times of
butyl esters of SCFA fragment from standard and biological sample. Butyl esters of
acetic acid (1), propionic acid (2), iso-butyric acid (3), butyric acid (4), iso-valeric
acid (5), valeric acid (6), internal standard (7), and hexanoic acid (8) represents the
di-butyl ether as a side product of butylation that did not co-elute with the sample
analytes.
A representative chromatogram of the SCFA butyl esters is shown in Figure 2-1.
The total SCFAs were increased after RS4 intervention as expected (Figure 2-2). Acetate
made up the majority of SCFA present at 60% of the total SCFAs before and after both
CF and RS4 interventions (data unshown). Propionate (50.2%), butyrate (69.5%),
valerate (44.1%), isovalerate (20.3) and hexanoate (19.2%) were significantly increased
post RS4 intervention from baseline as expected. Interestingly a 25.6% decrease in
isobutyrate was observed following RS4 diet.
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Figure 2-4: Effects of RS4 on fecal SCFAs abundance before and after RS4
intervention (* p ≤ 0.05,)53
2.4

Supplementary protocols attempted and Results.

Prior to optimizing the methods in section 2.2.2 and 2.2.3 we attempted to
replicate two previously published methods to extract and analyze SCFA Garcia-Villalba
et al., 201252 and Zheng et al., 201354. The working protocol according to Zheng et al.,
201354 is briefly as follows: 50mg (25-150 is acceptable) was weighed in a 30mL test
tube. 1,000µL of 0.005 M aqueous NaOH was added to the fecal sample and
homogenized for ten minutes, sonicated for ten minutes, and finally centrifuged at
13,200rpm for 20 minutes. A 500µL aliquot of supernatant fecal water was transferred
into a 10mL glass tube where10µL of internal standard (200ug/ml propionic2,2-D2),
250µL of water are added. Sample derivatization occurred by adding 500µL of
propanol/pyridine (3:2), and 100µL of Propyl Chloroformate (PCF) to the 10 mL glass
tube with prepared sample. The sample was then vortexed for ten seconds and sonicated
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for one minute. 300µL of hexane was added into the glass tube, vortexed for one minute,
let stand for ten minutes and centrifuged at 2,000rpm for five minutes. 200µL of the
upper hexane layer was transferred to a vial as the first extraction. Another 200µL of
hexane was added into the glass tube, vortexed for one minute, let stand for ten minutes
and centrifuged at 2,000 rpm for five minutes. An additional 200µL of upper hexane
layer was transferred to the vial with the first extraction in it followed by adding a small
amount of anhydrous sodium sulfate for water absorption and vortexed for 15 seconds.
Standards of each SCFA were prepared and initially ran per protocol on the GCMS which resulted in no visible peaks on the chromatogram. The heating scheme of the
GC-MS analysis was then altered by gradually raising the temperatures however the
temperature limit was eventually reached. The flow rate was increased and peak began to
appear, however they exhibited “tailing” which exhibits a wide tail-end of the peak
typically caused by a dirty column. This led to questioning the capabilities of the column
that was used regarding polarity, solute, or solvent conflict however the DB-5ms (5%
phenyl) methyl polysiloxane should behave the same as the column indicated in the
protocol. The program was run several times with only hexane in an attempt to clean the
potentially dirty column which eventually eluted cleaner peaks. Figure 2-3 shows an
example chromatogram with acetic acid laid on top of the blank. There are a couple of
early peaks (< 4.00 minutes) and then a group of peaks at approximately 18 minutes. Per
protocol acetic acid should elute < 3.00 minutes concluding that the peaks present are
false. Figure 2-4 shows propionic acid laid on top of the blank. The only peaks that differ
between blank and sample are the two peaks shown at 18 min. Again, the reference peaks
per protocol eluted < 5.00 minutes concluding that these peaks were also false. Figure 2-5
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shows butyric acid laid upon the blank. The only two peaks that deviate from the blank
appear very early, before the expected acetic acid and propionic acid which also conclude
these peaks as false. Through further adjusting of the temperature scheme, peaks were
identified for acetate, propionate, and butyrate standards all of which were at the same
concentration by calculation however appeared different levels on the chromatogram,
pipetting technique, multiple pipettes, and again column cleanliness were investigated.
Peaks began to show at 2.00 minutes (acetate), 2.60 minutes (propionate), and 4.20
minutes (butyrate) however these peaks exhibited fronting so further concern grew
regarding a more polar column, ramp speed and gas flow. The GC-MS was also changed
from split to splitless mode which exhibited no change in chromatogram. Further
adjustments with this system resulted in ultimately losing the peaks on the
chromatogram.
A b u n d a n c e
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Figure 2-5: Acetic acid vs. blank chromatogram
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Figure 2-6: Propionic acid vs. blank chromatogram
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Figure 2-7: Butyric acid vs. blank chromatogram
At this point with concern over the success of the derivatization reaction so a
second protocol that was simply an extraction, void of any derivatization was attempted.
The working protocol used for Garcia-Villalba et al., 201252 is as follows: fecal samples
were weighed to the nearest 100mg in a 30mL glass tube. The samples were suspended in
1mL of water with 0.5% phosphoric acid per 0.1g of sample. Samples were then vortexed
for two minutes and centrifuged at 17,949xg for ten minutes. The supernatant was then
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pulled off and the SCFAs were extracted with 1mL ethyl acetate per 1mL of supernatant.
Samples were then let stand for two minutes and vortexed followed by another
centrifugation at 17,949xg for ten minutes. 600µL of supernatant was then aliquoted into
a sampling vial where the internal standard propionic2,2-D2 was added at 500µM. The
samples were stored at -20oC until use. Upon GC-MS analysis, no peaks eluted onto the
chromatograph.
2.5

Limitations and Future Research.

The conclusion of this chapter resulted in an optimized method for fecal SCFA
extraction, derivatization and GC-MS analysis. As expected we observed increased
SCFA following RS diet31,55. The health consequences of butyrate and propionate, both
of which were increased following RS4 consumption are noted above. Valerate is also of
interest as it and propionate have been found to influence insulin-sensitivity in
adipocytes55. Interestingly isovalerate (commonly associated with protein creation) was
increased following RS4 consumption; this finding is unique as prior research found a
decrease in isovalerate following RS consumption56. Further research is needed to
understand the full biological effect of RS4 on SCFA production via microbial
fermentation in the gut.
The optimization of this protocol leaves a resource for future investigators and
elsewhere (we have demonstrated usefulness of this protocol for human subject research
through our publication) to study fecal SCFA levels. The derivatization method in the
protocol above produces –butyl esters which are of optimum size to study SCFA57. Of
important note this method was also attempted using BF3-M which resulted in the
formation –methyl esters which are ideal to analyze medium and long chain fatty acids.
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Experimentation with BF3-M ran short due to lack of time. To move forward an optimal
internal standard (IS) needs to be determined to quantify these fatty acids in samples. An
optimal IS would fall into the same range on the chromatogram that MCFAs would elute.
It is also important to investigate the expected fecal concentrations, elusion times, and
machine capabilities.
A limitation to this method is that once analyzed via GC-MS, roughly a quarter of
the duplicate samples had concentrations that were not closely related. When the samples
are being homogenized it is difficult to ensure a homogenous slurry as the consistency
and content of the sample is different throughout. Rotating the homogenizer in a circular
motion broke down the frozen sample more rapidly than direct pressure to the sample.
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CHAPTER 3. APPLICATIONS IN MATABOLOMICS RESEARCH
3.1

Introduction
The obesity epidemic over the past several decades has significantly impacted the

need for effective prevention, treatment and maintenance strategies for obesity and its
comorbidities. One mechanism to impact MetS is dietary intervention. In a previous
report, Nichenametla et al., 2014 found that an RS4 diet lead to 7.2% lower mean
cholesterol (TC), 5.5% lower non-HDL cholesterol and a 12.8% reduction in HDL in
individuals with MetS52. Many studies report the benefit of incorporating fiber and other
nutrient dense food items to the diet to combat MetS21,58.
Diet has been found to variably impact the composition of the microbiome in both
animal models and human dietary interventions. Physiological response and level of
change varied by the individual however are attributable to type of RS consumption32.
Response of the microbiome is also substrate specific. RS4 consumption increased
Bacteroidetes, Actinobacteria, Bifidobacterium adolescentis, and, Parabacterium
distasonis while decreasing Firmicutes in healthy individuals, whereas RS2 increased
Ruminococcus bromii and Eubacterium rectale32. This study raises the question if RS4
will improve the Firmicutes:Bacteroidetes ratio in individuals with MetS as it did in
healthy individuals. In healthy adults RS2 was also found to increase Bifidobacterium
adolescentis and Ruminococcus bromii which supports the findings above31.
Obesity and MetS are both associated with inflammatory conditions throughout
the body. IL-6 and TNF-α are proinflammatory cytokines secreted by adipose tissue that
are commonly linked to obesity and insulin resistance59,60. RS2 consumption in
individuals with T2DM was found to significantly decrease TNF-α but had no effect on
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systemic IL-6 or adiponectin61. Gargari et al., 2015 found RS2 consumption significantly
decreased TNF-α, HbA1C and triglycerides while also increasing HDL-cholesterol62.
Adoponectin is a protein derived from adipocytes that is negatively associated with waist
circumference and MetS63. In diabetic rats RS consumption increased the concentration
of circulating adiponectin64. In mice, cecum samples are commonly used to investigate
SCFA production as this is where SCFAs are most abundant. Mice research gives
investigators a base for human intervention studies.
The objective of this project were to investigate the immunometabolic effects of
RS4 and apply the method from Chapter 2 to metabolomics research. The specific aims
of this project were: 1) to investigate how RS4 modulates the gut microbiome in
individuals with MetS; 2) to determine if RS4 is altering lipid, glucose and
anthropometric measurements in individuals with MetS; 3) to investigate if there is an
association between changes in gut microbiome and lipid, glucose, anthropometrics and
fecal SCFA levels post-RS4 intervention; and, 4) to investigate the effect of RS4 diet on
cecum concentrations of SCFAs in mice.
3.2

Materials and Methods

The methods listed directly coincide with our already published data by Liu et al., 201665
(3.2.1) and Nichenametla et al., 20142 and Upadhyaya et al., 201653 (3.2.2-3.2.7).
3.2.1

Mice and Participants

Mice data used in this study were a part of another study65 whose objective was to
investigate the effects of RS4 in a genetically induced obese model of mice, KK.Cg-Ay/a
(Jackson Laboratories, Bar Harbor, ME). In brief, Six-week old mice were randomly
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grouped for feeding with RS4 and standard (control) diets. During the first three weeks,
mice were allowed to acclimatize and fed standard rodent chow, LabDiet® 5001 (Purina,
Saint Louis, MO). Animals were then switched to experimental diets formulated based on
AIN 93 either with (23.5% - RS4 diet) or without (0% - regular/control diet) RS4.
Animals were fed experimental diets for 13 weeks followed by termination (CO2
asphyxiation).
For human data, participants are the same cohort as indicated in section 2.2.1.
3.2.2

Fecal Genomic DNA extraction

Genomic stool DNA was extracted from human fecal samples using the QIAamp
DNA Stool Mini Kit (QIAGEN Inc., Valencia, CA) according to the manufacturer’s
instructions. Initially, 0.3-0.5g of each fecal sample was weighed into an appropriately
labeled 15mL tube. ASL buffer was then added to the specimen at 10mL/g feces
followed by sufficient vortexing to achieve homogenous distribution of the sample. The
sample was then placed in a water bath at 95oC for three minutes and subsequently
vortexed. Next, the samples were centrifuged for five minutes at 1500xg followed
removing a 1.6mL aliquot into a new 2mL tube. The samples were then heated at 95oC
for five minutes, vortexed for 15 seconds, and subsequently centrifuged for one minute at
20,000xg. 1.2mL of supernatant was then transferred into a new 2mL tube containing
InhibitEX and vortexed immediately until complete suspension of the tablet. The
suspension was then centrifuged down for three minutes at 20,000xg. All supernatant was
removed and again centrifuged down for three minutes at 20,000xg. 200µL of
supernatant was transferred to a new 2mL tube following the addition of 15µL of
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proteinase K and 200µL of AL buffer. Samples were vortexed for 15 seconds and
incubated at 70oC for ten minutes followed by an additional 2,000xg centrifugation for
one minute. 200µL of absolute ethanol was then added, vortexed, and centrifuged for one
minute at 2,000xg. The lysate was then transferred into a new spin column and
centrifuged at 20,000xg for one minute. The spin column was then transferred into a new
collection tube and 500µL of AW1 buffer was added. The sample was then centrifuged at
20,000xg for one minute. The transfer column was again transferred to a new collection
tube, 500µL of AW2 buffer was added, followed by a three minute centrifugation at
20,000xg. The column was then transferred into a new 1.5mL tube where 200µL of AE
buffer was added onto the column membrane. The sample was then incubated for three
minutes at room temperature and subsequently centrifuged for one minute at 15,000xg.
The concluding DNA sample was then kept on ice and quantified using the NanoDrop
system (NanoDrop Technologies, Wilmington, DE) and/or the quantified via the Qubit®
Quant-iT dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand Island, NY).
3.2.3

Gut microbiome and community structure analysis

Sample DNAs were sent to Second Genome (South San Francisco, CA) for
metagenome sequencing and operational taxonomic unit (OTU) identification. Briefly,
samples were enriched for bacterial 16S V4 rDNA region, DNA was amplified utilizing
fusion primer designed against the Illumina (San Diego, CA) flow cell adapters and
indexing barcodes. Each sample was PCR-amplified with two differently bar coded V4
fusion primers. For each sample, amplified products were concentrated using a solidphase reversible immobilization method for the purification of PCR products and
quantified by electrophoresis using an Agilent 2100 Bioanalyzer® (Agilent
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Technologies, Santa Clara, CA). Sequencing was carried out using Illumina MiSeq
platform following standard protocols for 250 cycles with custom primers designed for
paired-end sequencing. Using Quantitative Insights Into Microbial Ecology or QIIME 5
and generated custom scripts (Second Genome), sequences were quality-checked and
demultiplexed to determine exact matches to the supplied DNA barcodes. Resulting
sequences were then searched against the Greengenes reference database of 16S rRNA
gene sequences, clustered at 97% by uclust (closed reference OTU picking). The longest
sequence from each OTU was then assigned taxonomic classification via Mothur's
Bayesian classifier, trained against the Greengenes database clustered at 98%. For
unidentified Greengenes OTUs, we cross referenced with closest hits from NCBI 16S
rRNA database with query cover (>90%), identity (>87%), and E value (<0.01).
3.2.4

Anthropometric measurements (Data previously collected and

retrospectively analyzed here)
Height and waist circumference were obtained, to the nearest 0.5cm by
stadiometer and Gulick tape respectively. Weight was determined by electronic scale
(Seca Gmbh & Co., Hamburg Germany) to the nearest 0.1kg. Dual-energy x-ray
absorptiometry (DXA) (Hologic QDR Discovery A, Waltham, MA) was used to analyze
body composition at visit 1, 2 and visit 4. Digital sphygmomanometers were used to
measure blood pressure.
3.2.5

Blood glycemic and lipid variables (Data previously collected and

retrospectively analyzed here)
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Overnight fasting blood was collected at each visit (Figure 2-1) by venipuncture.
10mL of peripheral blood was collected in heparin-coated Vacutainer tubes (BD
Biosciences, Franklin Lakes, NJ). Immediately following collection 40µL of blood was
analyzed using the Cholostech LDX point-of-care analyzer (Alere Inc, Waltham, MA)
with lipid profile and glucose cassettes (Lipid Profile GLU, Alere Inc, Waltham, MA)
according to the manufacturer’s instructions to analyze blood glucose, total cholesterol
(TC), low-density lipoprotein cholesterol (LDL), high0density lipoprotein cholesterol
(HDL), non-HDL cholesterol (non-HDL), triglycerides (TGC) and TC/HDL levels.
Postprandial glucose was analyzed two hours after breakfast or lunch using a FreeStyle
Freedom Lite blood glucose meter (Abbott Diabetes Care Inc, Alameda, CA) according
to the manufacturer’s instructions. Hemoglobin A1C (HbA1C) was determined in
duplicate using the Human HbA1C kit (Crystal Chem, Downers Grove, IL) according to
the manufacturer’s instructions and expressed as percentage of total Hb.
3.2.6

Blood biomarkers

Interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα) were determined in
serum using Human Il-6 ELISA Ready-SET-Go!® (Catalog Number: 88-7066) and
Human TNF alpha ELISA Ready-SET-Go!® (Catalog Number: 88-7346) kits
respectively, according to the manufacturer’s instructions (eBioscience, San Diego, CA).
Initially, each well of the Corning Costar 9018 ELISA plate was coated with 100µL of
capture antibody in 1X Coating Buffer, followed by an overnight incubation at 4oC.
Using 250µL/well Wash Buffer and a multichannel pipette, wells were aspirated and
washed three times following a one-minute soaking to increase washing efficiency. Wells
were then blocked with 200 µL of 1X ELISA/ELISPOT Diluent and incubated for one
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hour at room temperature followed by another aspiration and washing. Lyophilized
standards were reconstituted with deionized water (DI) and allowed to set for 15 minutes
with gentle agitation. 1X ELISA/ELISPOT Diluent was used to dilute the reconstituted
standards from 1.5625 to 200pg/mL and 3.90325 to 500pg/mL and IL-6 and TNFα
respectively; 100µL of this solution was also used to serve as blanks. 100 µL of each
serum sample and standard was added to its appropriate well in duplicate. The plates
were then sealed and allowed to incubate at room temperature for two hours. The wells
were subsequently aspirated and washed five times following the previously mentioned
protocol. 100µL of detection antibody diluted in 1X ELISA/ELISPOT Diluent was added
to each well and then incubated for an hour at room temperature. As previously stated
plates were then aspirated and washed five times. 100µL of Avidin-HRP was added to
each well and incubated at room temperature for thirty minutes. Aspiration and washing
of the plate then followed as previously stated five times. 100µL of TMB solution was
then added to each well and incubated at room temperature for fifteen minutes. Stop
solution (1M H3PO4) was then added at 50µL to each well and read at 450nm and 570nm
on the plate reader.
Plasma adiponectin levels were detected by Human Adiponectin
radioimmunoassay (RIA) according to the manufacturer’s instructions (Linco Research,
St. Charles, MO) in the Swine Reproductive Physiology Laboratory at South Dakota
State University. Dr. Jeffrey Clapper conducted portions of this experiment where
radioactive materials were used. This protocol was performed twice; first to optimize the
assay and secondly to run the unknowns. This RIA was performed across two days: day
one for initial set-up and day two for running the assay.
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Optimization: Initially tubes were labeled and organized per sample including the serial
dilutions of the human adiponectin standard (STD). The STD was diluted from 200-0.78
ng/mL. Next, 300µL of Assay Buffer was added to tubes 3-4 representing the NonSpecific Binding (NSB) tubes, 200µL was added to tubes 5-6 representing the reference
tubes or 0ng/mL, 175µL to tubes 25-27, 150µL to tubes 28-30, and 100µL was added to
the remaining tubes in the assay. Next, 100µL STDs were added in tubes 7-24 from
lowest to highest, in duplicate. Quality Controls (QCs) were added to tubes 34-39
representing QC Low 3.125, DC Low 25, and QCLow 200 in duplicate respectively.
Next, 25 µL of plasma sample “SNA 4-9-13” of test sample was added to tubes 25-27,
50µL to tubes 28-30, and 100µL to tubes 31-33. Next, 100µL of 125 I-Human Adiponectin
was added to all tubes followed by the addition of 100µL of Human Adiponectin
antibody (AB) to all tubes except for tubes 1-4. All tubes were then vortexed, covered,
and stored overnight at 4oC. The next day, 10µL of Rabbit Carrier was added to all tubes
except tubes 1-2 followed by the addition of 1mL of cold Precipitating reagent (2nd AB).
All tubes were then vortexed and incubated for 20 minutes at 4oC followed by a 20
minute centrifugation at 2,000 xg also at 4oC. Immediately following, the supernate was
decanted into a waste jug and patted onto absorbent paper. Tubes were then counted on
the gamma counter, one minute per set of tubes.
Unknowns: Once optimized, the experiment was then repeated using the same protocol
as previously stated for the unknown samples with the following modifications. Initially
tubes were labeled and organized per sample including the serial dilutions of the human
adiponectin standard (STD). The STD was diluted from 200-0.78 ng/mL. Next, 300µL of
Assay Buffer was added to tubes 3-4 representing the Non-Specific Binding (NSB) tubes,
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200µL was added to tubes 5-6 representing the reference tubes or 0ng/mL, and 100µL
was added to the remaining tubes in the assay. Next, 100µL STDs were added in tubes 724 from lowest to highest, in duplicate. Quality Controls (QCs) were added to tubes 2530 representing QC Low 3.125, DC Low 25, and QCLow 200 in duplicate respectively.
Next, 100µL of each unknown plasma sample was added to their respective tubes in
duplicate. Then 100µL of 125 I-Human Adiponectin was added to all tubes followed by
the addition of 100µL of Human Adiponectin antibody (AB) to all tubes except for tubes
1-4. All tubes were then vortexed, covered, and stored overnight at 4oC. The next day,
10µL of Rabbit Carrier was added to all tubes except tubes 1-2 followed by the addition
of 1mL of cold Precipitating reagent (2nd AB). All tubes were then vortexed and
incubated for 20 minutes at 4oC followed by a 20 minute centrifugation at 2,000 xg also
at 4oC. Immediately following the supernate was decanted into a waste jug and patted
onto absorbent paper. Tubes were then counted on the gamma counter, one minute per set
of tubes. Samples were then rerun if the values obtained for each duplicate didn’t match
within 10% of each other. RIA sensitivity for this assay was 1085 ng/mL. Inter- and
Intra-assay coefficients of variance were 5.0% and 11.7% respectively.
3.2.7

Dietary assessment (Data previously collected and retrospectively

analyzed here)
A previously validated 3-day food-frequency questionnaire (Appendix 1) based
on common items in the Hutterite diet was used to assess dietary intake over two
weekdays and one weekend day for each timepoint. Nutritionist ProTM (Axxya,
Woodinville, WA) was used to for diet analysis and nutrient break down of all items
listed on the food-frequency questionnaires.
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3.2.8

Mouse cecum sample SCFA analysis

Previously collected cecal tissues, from mice fed an RS4 diet, which were snap-frozen in
liquid nitrogen immediately after sacrifice and stored at -80 0C. For each pooled sample,
three cecal tissues were pooled together (>500mg in total weight) and mixed with 1mL of
internal standard (2-ethylbutyric acid in 1-butanol, 0.25 mg/ml). Samples were mixed by
one minute vortexing followed by the addition of 0.5mL of hexane and 2mL of HCl-B.
Each sample was sonicated for five minutes before purging with an inert helium gas and
immediately sealed. Each sealed container was incubated in a water bath at 60 0C
overnight in order to catalyze the derivatization of SCFA analytes. Upon returning to
room temperature, 1.5mL of additional hexane and 15mL of deionized water were added
to each sample, vortexed for 1 min each and then centrifuged at 3000xg for two minutes.
The top organic layer (~2mL) was transferred into a 5mL graduated vial before blowing
down with helium to one-fourth of the volume, increasing the final concentration of
internal standard from 0.25mg/ml to 1mg/ml. Finally, each sample was transferred into
150µL insert inside the sampling vial and ~100mg of anhydrous sodium sulfate was
added prior to being frozen at -20oC. GC-MS analysis was carried according to the
protocol above in section 2.2.3.
3.2.9

Statistical analysis

Data was analyzed comparing end-points for outcome variables in CF and RS4
groups, or pre- and post-intervention measures. For mouse SCFA cecum samples
intergroup comparisons were performed using Student’s t-test. Linear mixed effects
models (SAS MIXED procedure) were used to compare the effects of RS4 and CF on
physiologic parameters. All models included variables for colony and season, where
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colony was a surrogate for randomization sequence and season was a surrogate for
crossover treatment period. General linear mixed models were also used to compare the
effects of RS4 and CF on microbial abundance using R software package66. To correct
for multiple comparisons, a false discovery rate (FDR or Benjamini Hochberg method)
correction was used to adjust p values (adjusted p is represented as q). For pre- and postintervention comparisons paired t-test (Wilcoxon signed-rank test for non-normal data)
was used, while student’s t-test (Mann-Whitney signed-rank test for non-normal data)
was used to compare two different diet groups. Where necessary, data was
logarithmically transformed to achieve normality. Intra-relationships among parameters
or bacterial species and inter-relationships between parameters and microbiota were
carried out using Pearson’s linear correlation coefficient (r). Correlation matrices and
heat maps were generated using various R-packages. The data were presented as means ±
S.E.M, unless otherwise noted. A p value of 0.05 or less was considered significant,
while p value of 0.05 to 0.09 was considered trend or approaching significance.
3.3

Results

RS4 was found to improve body composition, dyslipidemia, as well as glucose
metabolism in this cohort with MetS. Percent body fat, TC, HDL, and nonHDL were
significant lower after RS4 consumption compared to CF (Table 3-1). A trend towards
lower waist circumference, fasting glucose, glycated hemoglobin, LDL cholesterol, and
TNF-α was also observed following RS4 diet compared to CF. Adiponectin was
significantly followed the same trend as previously mentioned however it was
significantly increased between baseline and RS4 consumption. Waist circumference,
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TC, HDL, nonHDL, and IL-6 were significantly reduced from baseline to post RS4,
while LDL trended towards significance.
Table 3-1. Means of biological parameters at baseline and at the end of intervention
periodsa53
p: Post
CF
BL

Post CF

Post RS4
vs Post
RS4

p: BL
vs post
RS4

Anthropometrics
Weight (kg)

90.9±3.4

91.0±0.4

91.6±0.4

NS

NS

BMI (kg/m2)

32.8±1.1

32.8±0.1

32.7±0.1

NS

NS

Waist (cm)

109.0±2.8

108.8±0.9

106.6±0.9

0.06

0.02

Systolic BP (mm
Hg)

135.0±3.9

134.6±3.5

137.5±3.5

NS

NS

Diastolic BP (mm
Hg)

73.7±2.2

68.6±2.0

73.3±2.0

NS

NS

% Body Fat

37.0±1.8

37.7±0.3

37.3±0.3

0.05

NS

Fat-free mass (kg)

58.8±3.0

58.8±0.3

58.9±0.3

NS

NS

106.5±4.1

111.5±4.2

101.9±4.3

0.09

NS

Glycemic Variables
(mg/dL)
Fasting glucose
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Postprandial
glucose

113.5±11.8

124.3±7.3

114.3±7.5

NS

NS

HbA1C (% of total
Hb)

5.89±0.3

5.81±0.1

5.75±0.1

0.08

NS

Total cholesterol

196.6±11.6

192.8±4.6

187.8± .9

<0.001

0.01

HDL cholesterol

43.6±3.3

44.1±1.3

39.8±1.3

<0.01

0.001

LDL cholesterol

122.7±10.1

117.4±5.6

118.0±6.1

0.06

0.06

NonHDL cholesterol 153.1±11.8

148.4±4.6

147.5±4.9

<0.01

0.03

Lipid Variables
(mg/dL)

TC/HDL (ratio)

5.0±0.5

4.7±0.2

5.1±0.2

NS

NS

Triglyceridesb

161.5±19.9

144 (119176)

138 (110173)

NS

NS

IL6 (pg/mL)

1.3±0.2

1.0±0.2

0.8±0.2

NS

0.04

TNF-α (pg/mL)

7.9±4.2

9.9±1.2

6.0±1.3

0.08

NS

Adiponectin
(g/mL)

8.3±1.5

10.8±0.4

10.0±0.4

0.02

<0.01

Blood Biomarkers

a

Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline
values.
b
Geometric mean and confidence interval are given for log-transformed triglyceride
endpoints.
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p-value ≤0.05 were considered significant, between 0.05 and 0.09 considered as
approaching significant (trend), when greater than 0.09 is shown as NS (non-significant);
Linear mixed model analysis was used to determine significance between post-CF and
post-RS4, paired t-test for baseline vs post-RS4, n=18 to 20 due to missing data points.
BL: baseline; CF: control flour; RS4: resistant starch type 4; BMI: body mass index; BP:
blood pressure; Hb: haemoglobin; HDL: high density lipoprotein; LDL: low density
lipoprotein; TC: total cholesterol; IL6: interleukin 6; TNF-α: tissue necrotic factor alpha.

Table 3-2. Estimated nutrients intake at baseline and at the end of intervention
periodsa53
p: post CF
Nutrients
BL
Post CF
Post RS4
vs post RS4
Caloric intake (kcal/d)

1774±154

1528±121

1716±128

NS

Protein (g/d)

76±7

72±5

62±4

NS

Carbohydrate (g/d)

218±21

220±19

212±18

NS

Total fat (g/d)

68±7

60±5

53±5

NS

Cholesterol (mg/d)

415±40

442±38

407±35

NS

Saturated fat (g/d)

25±3

22±2

21±2

NS

Monounsaturated fat (g/d)

26±3

22±2

19±2

NS

Polyunsaturated fat (g/d)

10±1

9±1

7±1

NS

Total dietary fibre (g/d)

18±2

16±2

27±2

<0.001

a

Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline
value analysed by linear mixed model; n=18-20 due to missing data points.
BL: baseline; CF: control flour; RS4: resistant starch type 4
16S rRNA sequencing of the gut microbiome resulted in 5,949 OTUs the two
major phyla present being ~78% Firmicutes and ~9% bacteroidetes. To avoid carry over
affects between the two week washout period between diets a permutational multivariate
analysis of variance was performed resulting in no significance which concludes all
observations observed are directly related to diet. A principle coordinate analysis (Figure
3-1) shows 26% and 13% variation between post CF and post RS4 consumption on axes
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1 and 2 respectively. RS4 consumption differentially modulated 71 OTUs, 65 Firmicutes,
3 Bacteroidetes, 1 Actinobacteria, 1 Tenericutes, and 1 Proteobacteria. Interestingly, all 3
Bacteroidetes were increased by RS4 consumption whereas the Firmicutes had a mixed
response.

Figure 3-1: Separation of the microbiome post intervention in RS4 and CF groups.
Two-dimensional principal coordinate analyses (PCoA) based on the weighted
UniFrac distance between samples, given the abundance pf 5,831 taxa present in at
least one sample (n=19). Axes 1 and 2 explain 26% and 13% of the variation,
respectively (p=0.01)53

Firmicutes and Bacteroidetes are commonly studied in relationship to the obese
microbiome. Both phyla contain both beneficial and less desired microbes. Figure 3-2
shows that overall the RS4 intervention reduced the Firmicutes:Bacteroidetes ratio, a
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desired attribute of prebiotic fibers, whereas CF increased this ration. Of important note
alterations of this ration are highly individual specific, grouped together these trends were
observed. Variation of the gut microbiome is dependent on substrate availability for
microbial fermentation as well as total caloric intake36. Seasonal variations of the
microbiome have been reported in previously, attributed to fresh fruit and vegetable
availability in the Hutterite diet35; this was ruled out in this case as the study period did
not overlap with winter months. Table 3-2 indicates macronutrient intake did not vary
across study periods based on the self-reported 3-day diet questionnaire. Total dietary
fiber was however significantly greater after RS4, however caloric intake was not
significant.

Figure 3-2: The Firmicutes/Bacteroidetes ratio after intervention (n = 14). The
dotted line represents this ratio at baseline.53
A Pearson correlation analysis showed a potential link between significant
changes in the gut microbiota composition induced by RS4 and altered SCFA levels
shown in Figure 3-3. Acetate and butyrate levels were correlated (p < 0.05) with
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Ruminococcus lactaris (r = 0.54) and Oscillospira spp. (r = 0.41). Total SCFAs were
correlated with the abundance of two species: Methanobrevibacter spp. (r = 0.43) and
Ruminococcus lactaris (r = 0.52). Propionate and isobutyrate levels were linked to
Methanobrevibacter spp. (r = 0.65 and r = 0.79, respectively), Eubacterium dolichum (r =
0.42 and r = 0.43, respectively), Christensenella minuta (r = 0.39 and r = 0.59,
respectively), and Ruminococcus lactaris (r = 0.59 and r = 0.40, respectively), of which
the latter two were increased by RS4. These associations with specific microbes and fiber
were not found in the CF group.

Figure 3-3: Positive correlation of six bacterial species with increased SCFA levels in an RS4-specific
manner (all, p <0.05). Pearson coefficients are shown on heat map. #, the closest hit from the NCBI
16S rRNA database cross referenced with the OTU from the Greengenes database. †, species either
significantly enriched or approached significance in the RS4 group.53

In the KK.Cg-Ay/a mouse model, cecal butyrate was found to be significantly
enriched via RS4 consumption compared to control diet as shown in Figure 3-4. SCFAs
acetate and propionate were virtually undetected in these cecum tissues. Neither RS4 nor
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the control diet significantly enriched isobutyrate, valerate, isovalerate, and heaxanoate
concentrations.

Figure 3-4: Cecal butyrate concentration in KK.Cg-Ay/a mice fed with RS4 and
control diets. Data points represent the mean ± SEM (n = 3). *p<0.05, **p<0.01,
***p<0.001 compared with control diet group.65
3.4

Discussion

The results of this chapter further support the use of RS4 as a dietary supplement
relative to MetS symptoms. Waist circumference and % body fat were significantly
reduced by RS4 compared to CF, both of these variables may contribute to reduced
central obesity, the number one diagnostic criteria of MetS. Adiponectin was
significantly lower after RS4 compared to CF, however it was higher after RS4 compared
to baseline. The plasma reduction in TC, HDL, and nonHDL cholesterol was also
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observed in the parent cohort of this study2 This is undesirable adiponectin is inversely
related with MetS.
It has been well established that type and quantity of fiber in the diet differentially
modify the gut microbiome36. Here we found that 71 OTUs were differentially affected
by the supplementation of RS4, this finding was highly variable by each individual. The
Firmicutes:Bacteroidetes ration has been well established as a predictor of the obese
microbiome29,30.
The ability to correlate the outcome of the method optimized in chapter two with
results in this chapter was a significant outcome of this overall research study.
The mouse model studied in this chapter support the increased butyrate production in
this human population as found in chapter 2. Applying the SCFA extraction method to
intestinal tissue proved to be a challenge at first. The study protocol was initially
attempted following the same guidelines as described in section 2.2 using one cecum
sample; however, GC-MS resulted in undetectable concentrations of SCFA. In an effort
to save the remainder of these delicate samples, pools of three samples were established
to increase SCFA concentrations as well as using HCl-B overnight as a derivatization
reagent instead of BF3-B for 20 minutes. Of note, after the overnight incubation with
derivatization reagent, the sample completely dissolved into solution whereas before it
appeared to be washed clean. This resulted in detectable and quantifiable SCFA
concentrations.
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CHAPTER 4 . SUMMARY
The goal of this research was to optimize a matabolomic assay to quantify fecal
short chain fatty acids (SCFAs), a byproduct of microbial fermentation in the gut, and to
apply this assay to assess associations of various phenotypic outcomes of RS4
intervention in an adult population with MetS as well as in genetically induced obese
mice. This protocol was created for scientists at SDSU to extract, derivativatize, and
quantify short chain fatty acids from stool samples and may in future be extended to
quantify medium chain fatty acids from stool samples. Overall, metabolite profiles
related to the gut microbiota can offer deep insights on the impact of lifestyle and dietary
factors on chronic diseases, which is why metabolomics studies in gut microbiota related
research have increased in last few years. The protocol may be utilized for other complex
matrices such as intestinal samples, as described in Chapter 3. The resulting method
contains a one-step derivatization followed by a simple extraction. BF3-B and HCl-B
were chosen as derivatization reagents because the combination of these powerful acids
with methanol and/or butanol are efficient catalysts for the esterification of fatty acids67.
Naturally fatty acids are difficult to analyze due to their high polarity and volatility which
causes sample loss either in the air or by surface absorption. The addition of a
derivatization step causes esterification which attaches a functional group to the fatty acid
structure creating a larger more stable molecule which are easier to detect. The final
working protocol is as follows:
Chemicals:




Boron trifluoride-1-butanol (BF3-B)
Hexane (>97.0%)
1-butanol
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Sodium sulfate (granular, anhydrous, >99.0%)
Internal standard (2-Ethylbutyric acid 99%)
Helium (gas)
Deionized water

Instruments:










Vortex
Centrifuge
Pipettes
Balance
Water bath
30mL tube with Teflon cap
GC sampling vial
50mL centrifuge tube
Sonicator

IS prep:
(Prepare IS in butanol if no exact balance available and proceed with sample prep by
adding exactly 1mL of IS solution to the sample)
1. Prepare a 1.5mg/mL IS in 1-butanol (record the exact weight of 2-ethylbutyric
acid)
2. Pipette 1mL into 30mL tube
3. Record weight of 30mL tube + IS
Sample Prep:
1. Weigh at room temperature 800-1000mg (±0.1mg) in the tube with the IS
2. Add 500 µL hexane
3. Vortex for 1 min.
4. Add 2 mL HCl-B reagent
5. Vortex for 1 min.
6. Sonicate for five minutes
7. Purge the container with an inert gas (Helium)
8. Close and seal the container
9. The reaction is conducted at 100 ͦ C for 20 minutes
10. Cool it down to room temperature
11. Add 1.5 mL hexane
12. Vortex for 1min.
13. Add 15 mL H2O and vortex for 1 min.
14. Transfer to 50mL centrifuge tube
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15. Centrifuge for 2 min at 3,000g*min-1.
16. Transfer the upper organic layer into a 2 mL GC vial with or without 150µL insert
17. Add ~100mg sodium sulfate
18. Seal the vial and keep it at -20C
Stepping through this protocol one should note the importance of using a glass
vial to prevent any surface absorption of the volatile fatty acids. Teflon caps are used to
ensure an adequate and material/solvent compatible seal. Initially the IS was prepared at
2mg/ml in acetone, the solution was evaporated off via purging with in inert gas (either
nitrogen or helium pending availability) and the exact weight of the IS was obtained. This
method was found to be too variable due to solvent splashing and spilling pending air
flow rate. The concentration of IS was then reduced to 1.5mg/ml and directly prepared in
1-butanol. Upon the addition of hexane and the derivatization reagent, adequate mixing
must be performed as the sample tends to stick to the glass and/or lid. Proper mixing was
achieved via sample vortexing both upright and upside down for complete wash of the
sample tube. Also important to note is that the derivatization reagent must be closed
immediately after use as it reacts with water in the air. Sonicating the sample produces a
significant amount of heat, caution should be taken as to how the tubes are handled. Once
samples are purged with helium, the tube should be capped immediately. Heat is applied
in the water bath to help drive the derivatization reaction forward. After the water bath,
samples must be returned to room temperature before opening to prevent any loss of the
volatile acids.
The results of this research also support supplementation of RS4 into the diet of
individuals with MetS; however, a significant amount of research is still needed to
establish dietary reference intake values. We found that RS4 supplementation
significantly increased fecal SCFA (butyrate, propionate, hexanoate, valerate, and
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isovalerate) which directly correlated with beneficial gut microbiota. We also found that
RS4 supplementation significantly reduced waist circumference, TC, HDL, nonHDL, and
IL-6 which may provide alleviation of MetS and its comorbid diagnoses. Compared with
the CF, RS4 significantly decreased % body fat, TC, HDL, nonHDL cholesterol, as well
as adiponectin. RS4 supplementation in this cohort also reduced the
Firmicutes:Bacteroidetes ratio as well as promoted growth of several beneficial microbial
species. Taken together we found that RS4 in association with the gut microbiome elicits
beneficial immunometabolic health outcomes on adults with metabolic syndrome.
The results of this study lead to many future implications and study ideas such as
confirming the results by humanized gnotobiotic mouse model such as that described in
the drafted protocol in Appendix 2. This gnotobiotic mouse model would be used to
confirm that the results of the findings above were directly associated with gut microbial
change. In brief, stool from human RS4 responder would be orally gavaged into
gnotobiotic mice that would then be placed on RS4 or CF diet. The same parameters as
above would be studied on these mice. This mouse model was originally the plan of this
graduate study however due to university restrictions and lack of collaboration with
outside facilities in the local area; we were unable to conduct the experiment and the
protocol was left in draft form.

In conclusion, with the national trend of obesity and chronic diseases associated
with obesity continue to rise at an alarming rate; it is evident that research needs to be
completed to assist in reversing this epidemic trend. Overall, the research presented
within this paper were beneficial in understanding the effect of an ad libitum RS4 dietary
intervention on various health parameters in humans and mice. Even though some data is
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inconclusive within this experiment, a solid foundation has been established for future
research studies. The tools have been created and are ready for use to continue on with
this intriguing research on dietary interventions and their influence on microbial-derived
SCFA production.Implementing prebiotic and higher amounts of dietary fiber within the
diet suggest improved health outcomes. The outcomes of this research may contribute in
the development of future dietary guidelines of RS in the diet. With further research and
testing, I am hopeful for breaking evidence suggestive of creating a healthier nation.
This research should also help future clinical and mechanistic research.
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Appendix 1. Gnotobiotic IACUC Protocol

For IACUC Committee Use Only

This form will be updated yearly and expires December 31, 2013.

Proposal Number
Please destroy all old forms.

SOUTH DAKOTA STATE UNIVERSITY
ANIMAL USAGE FORM
EXPLANATIONS AND INSTRUCTIONS

Individuals from academic institutions that receive funding from federal granting agencies such as NIH,
NSF and USDA are required, by federal regulations, to follow specific guidelines concerning the care and use
of vertebrate animals (mostly mammals) used in their research. Part of these requirements include the
completion of an animal usage form which must be reviewed and approved by the university animal care
committee before grants utilizing vertebrate animals can be submitted, and before experiments utilizing
vertebrate animals can be initiated. Therefore, complete the form as completely and as clearly as possible and
send to University Veterinarian, Department of Veterinary Science, SAR 106, Box 2175, SDSU. If you have
any questions, call the University Veterinarian at 688-6528 or 688-6649.

SOUTH DAKOTA STATE UNIVERSITY
ANIMAL USAGE INFORMATION FORM
Instructions: Complete all items. If items do not apply, write "N/A" on the appropriate line. Send
form to Veterinarian, Animal Care and Use Committee, SAR 106, Box 2175, South Dakota State
Univ. (688-6649).
1.

Principal Investigator/Instructor: Moul Dey
11/15/2013

2.

Department:

Date:

Health and Nutritional Sciences

Campus Address: Bldg/Room Wagner Hall/ 449

Box 2203

E-mail: Moul.Dey@sdstate.edu
3.

Phones: Office 605 688 4050 , Laboratory 605 688 6169

, Emergency
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4.

Funding Agency or Department:

5.

a) Proposal Submission Deadline:

AES
11/15/2013

b) IACUC Approval Period (not to exceed 3 years): 11/26/2013-11/25/2016
6.

Project Title: Study of metabolic status and gut microbial profiles associated with human
fecal transplantation in a mouse model

7.

Animals to be used in the project:

A. Species

B. Number of
animals to be
acquired from
outside SDSU

Mouse

C. Number of
animals to be
utilized
involving no
pain* or distress

48

D. Number of
animals subjected to
pain or distress for
which appropriate
drugs will be used.†

E. Number of animals
subjected to pain or
distress for which
appropriate drugs will
adversely affect the
results**†

F. Total number
of animals (Cols.
C + D + E)

48

48

* Pain = pain induced for reasons other than normal animal husbandry practices (other than single or routine venipuncture
& non-irritating injections)
** An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used
must be included in this submission
† Must complete question 14

Source of Animals

Taconic Inc., Rensselaer, NY

Housing location: Building

ARW

Room TBD

If the animals will be housed & cared for in ARW, you must contact the ARW facility
manager (diane.baker@sdstate.edu, phone 605-688-6028) two weeks before the
anticipated arrival date.
Other
8.

For agricultural animals, will accepted management procedures and routine practices such
as castration and dehorning as described in the GUIDE FOR THE CARE AND USE OF
AGRICULTURAL ANIMALS IN RESEARCH AND TEACHING (Third Ed., 2010) be
used in the care of these animals?
(Available from http://www.fass.org/docs/agguide3rd/Ag_Guide_3rd_ed.pdf)
Yes

No. If NO, then describe exceptions.

9.
Provide a complete description of the proposed use of animals. You must refer to the
specific
sections and page numbers in your proposal or include on an attachment with a full
description.
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The principal objective of the proposed use of animals is to validate and extend our previous
findings in humans that showed resistant starch-type 4 (RS4), a chemically modified resistant
starch present in the wheat flour, promotes the metabolic health (Nichenametla et al., 2014).
Using human stool samples from this study; we would like to investigate the direct interaction of
RS4 with gut microbiota in a pre-clinical mouse model where we can customize the gut
microbiota profile unlike in humans. Hence, gnotobiotic mice model with a defined gut
microflora is the optimum model for human-to-mouse fecal-transplantation because these mice
associated with Altered Schaedler Flora (Table 1) show the potential to mimic human gut
microbial profile in mice . We are also able to directly reference a large database of prior work
using such humanized mice, especially for gut-microbiota associated obesity and metabolic
syndrome supporting the use of gnotobiotic mice.
Table 5: Altered Schaedler Flora [commensal, non-pathogenic?] also need original
reference
Taxon

Oxygen sensitivity

Identity

Fusiform EOS bacteria

Yes

Clostridium sp ASF356

Fusiform EOS bacteria

Yes

E. plexicaudatum ASF492

Fusiform EOS bacteria

Yes

Clostridium sp. ASF502

Fusiform EOS bacteria

Yes

Clostridium sp. ASF500

Lactobacillus acidophilus

No

Lactobacillus sp. ASF360

Lactobacillus salivarius

No

L. animalis & L. murinus ASF361

Bacteroides distasonis

No

Bacteroides sp. ASF519

Spiral shaped organism

No

Flexistipes phylum ASF457

Dietary interventions with RS-2 and RS-4 have been shown to attenuate various risk factors for
metabolic syndrome (MetS) characterized by several conditions such as insulin-resistance,
dyslipidemia, abdominal obesity and hypertension that ultimately lead to atherosclerosis and
cardiovascular disease (CVD) (Martinez et al., 2010; Brunner et al, 2002). As RS4 is chemically
modified and therefore can evade chemical digestion, it is however susceptible to microbial
fermentation in the colon, hence we are interested in showing how the interaction between RS4
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and gut microbiota renders a healthy outcome. Accumulating evidence suggests that gut
microflora play a central role in maintaining a balance between health and disease, including
MetS 29. Moreover, it has been postulated that there are different sets of gut microbiota based on
abundance in healthy individuals versus patients with MetS 68. Hence, we hypothesized that
dietary RS4 would prevent MetS by shifting the blood, lipid and gut microbial profiles towards a
favorable health-outcome after transplanting human fecal samples from MetS patients to
gnotobiotic mice. This gnotobiotic mouse model, once optimized, can be utilized for future
research concerning the microbiome which is the field of growing interest.
Prior to animal experiment, we will obtain the formulated control and RS4 feeds (Test Diet,
Richmond, IN) (Table 2). These isocaloric control and RS4 diets will eliminate the possible
effects of energy restriction in metabolic health of mice.
Table 2: Composition of experimental diets
Ingredients

Control Diet (%)

RS4 Diet (%)

31.77

27.07

0.00

23.5

Powdered cellulose

18.80

0.00

Casein – vitamin free

14.00

14.00

Dextrin

13.67

13.67

Sucrose

8.82

8.82

Soybean oil

8.00

8.00

AIN 93M mineral mix

3.50

3.50

AIN 93M vitamin mix

1.00

1.00

Choline Bitartrate

0.25

0.25

L-Cystine

0.18

0.18

Wheat starch

1

Resistant wheat starch type-4

2
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t-Butylhyrdoquinone
Energy content (Kcal/g)
1

2

0.0008

0.0008

3.3

3.3

Wheat starch is Midsol TM 50 with energy content of 359.5 Kcal/100 g.
Resistant starch is Fibersym RW with energy content 56.5 Kcal/100g.

Overall mice experiment will be carried out in two phases:
Phase I: Microbial effects of animal health status
To know how the microbiome of mice transplanted with human feces responds to RS4 dietary
intervention, we will use a gnotobiotic mouse model consisting 5-8 week old female
heterozygous Swiss nude mice randomly divided into four groups (12 mice per group, two
sacrificed for baseline values, and five mice per final two cages) for human fecal transplantation
(Table 3). We chose this strain because of its availability with a defined gut-microbiota. All mice
will be kept in more stringent specific pathogenic free housing to prevent contamination with any
unknown bacteria
Table 3: Mouse groups and treatments
Group

No. of animals

Dose/treatment

2 Control

12 (-2 sacrifice, 5+5: final)

200µL preRS4

B (B1+B2)

Control

12 (-2 sacrifice, 5+5: final)

200µL post-RS4

C (C1+C2)

RS4

12 (-2 sacrifice, 5+5: final)

200µL preRS4

D (D1+D2)

RS4

12 (-2 sacrifice, 5+5: final)

200µL post-RS4

A
(A1+A2),
donors

Diet

After one week of acclimatization, mice will undergo a fecal microbial transfer (FMT) from an
individual whose response to RS4 was greatest compared to other participants. Response to RS4
was analyzed on several parameters including change in body fat, weight, total cholesterol,
fasting blood glucose, metabolic status, and specific bacterial abundance. One pre-RS4 and one
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post-RS4 fecal sample will be homogenized and added to 5mL of PBS to create the solution for
subsequent gavage. 200µL of prepared fecal solution will be gavaged into the stomach of the
recipient mice through plastic oral tubing. After fecal transplantation four groups each with 11
mice (Table 3) will be housed separately to avoid possible cross-contamination. One mouse
from each of the four groups as indicated in Table 3 will be sacrificed prior to FMT to obtain
cecal short chain fatty acids analysis. After three weeks, the blood samples will be collected from
saphenous vein to take the basal readings of blood glucose and lipid profiles before dietary
intervention. This method of blood collection does not involve anesthesia and is less stressful to
mice. Collection of fecal pellets followed by fecal culture will be performed every week for
analysis of gnotobiotic status throughout the entire experiment. At this point one additional
mouse will be sacrificed from each group for basal body composition prior to dietary
intervention, leaving the final total of ten mice per group.
Phase II: Impact of dietary intervention with RS4 on animal health status
Phase II of this experiment includes the addition of RS4 chow to animal groups C and D as
indicated in Table 3. Mice will be observed daily and monitored for any abnormal signs of pain
and distress, appearance, appetence and behavior. All mice will be weighed weekly to monitor
the feed intake and growth curve. We will consult to attending veterinarian for appropriate care,
treatment or euthanasia, if and when any mouse develops visible signs of distress. All mice will
be euthanatized with CO2 asphyxiation 21 days post-dietary intervention (week 7), and blood will
be collected through cardiac punctuation immediately after the sacrifice. Body composition
analysis will be performed at the Materials Evaluation and Testing Laboratory (METLAB) in the
College of Engineering at SDSU. Biological specimens including the entire gut, mesenteric
lymph node, mesenteric fat, spleen, and liver will be collected, and aliquots of tissue samples will
be snap-frozen in liquid nitrogen or kept in 10% formalin for subsequent gene expression
experiments or histopathological examinations, respectively. The remainder of the mouse will be
disposed and incinerated later. The summarized timeline of the proposed experiment is shown in
Table 4.
Table 4: Schedule of the proposed experiment
Week

Treatment

Comments

0

Acclimatization

Daily observation; regular chow diet

1

Fecal Microbial Transplant

Phase I: Blood collection through
saphenous vein, 200µL oral gavage of either
preRS4 or post-RS4 human stool samples.
One animal from each of the four groups
will be sacrificed for baseline values

4

Introduction of control or RS4 chow to Phase

II:

Blood

collection

through
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7

designated groups

saphenous vein, one animal from each of the
four groups will be sacrificed for analysis of
microbial effects pre-diet intervention

Mice sacrifice and tissues collection

CO2 euthanasia
Body composition; cardiac puncture; snapfrozen tissues in liquid N2; fixed-tissues in
10% formalin

Routine monitoring of animal health includes daily observation of any signs of pain and distress, weekly
measurement of body weight, and weekly microbial culture of stool samples.

10.

Provide specific design information that supports your rationale for involving animals and
appropriateness of species and numbers to be used. (Note: This proposal may be referred
to a statistician to verify appropriateness of animal numbers.)
The Swiss nude mice model has been well established for human fecal transplantation. The
design of this project is based on previous literature reports on human-to-mouse fecal
transplant models. As similar kind of fecal transplantation studies are not feasible in
humans, appropriate mouse model is. The numbers of animals in this study are consistent
with literature reports using mouse model for human fecal transplantation. The study
reporting human-to-mouse fecal transplant model is given below:
We are also able to directly reference a large database of prior work using such humanized
mice, especially for gut-microbiota associated obesity and metabolic syndrome supporting
the use of gnotobiotic mice.
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., . . . Gordon, J.
I. (2013). Gut microbiota from twins discordant for obesity modulate metabolism in mice.
Science, 341(6150), 1241214. doi: 10.1126/science.1241214

11.

Alternatives to Painful Procedures:
If painful or slightly painful procedures are to be used, provide a written narrative
description of the specific electronic database/information search (in addition to reading
journals/periodicals) which was performed (for example, the Animal Welfare Information
Center) along with the specific key words to help determine that alternatives are not
available.
Date search was conducted: 11/04/2013
Key words used:
Gnotobiotic, Gut microbiota, Metabolic syndrome, Resistant Starch,
Mouse model
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Databases searched:

Pubmed

Period of time covered by search:

All years

Narrative description describing the results of the alternatives search and the impact on
the use of animals in this project:
Oral gavage is the straight-forward and less painful than other techniques for the fecal
transplantation. Blood collection through saphenous vein is less painful because it is less
invasive than retro-orbital sinus, which may have more complication.
12.

Check if proposal involves (refer to IACUC page on InsideState for more information)
Invasive Procedures (e.g. multiple injections, multiple blood sampling, surgery,
catheterization)
X

Pain or other Stress (e.g. injections, disease, surgery, Freund's adj., ascites fluid
production)
Deprivation (e.g. limiting food, water, light)
Other (e.g. fright, noise, physiological stresses, etc.)

Briefly describe any items checked above and explain the need for these in the project.
Only one-time oral gavage will be used during the entire study. We will also collect
the blood form saphenous vein twice three weeks apart.
13.

A.

For any of the procedures described above in question #13, identify the
pharmaceuticals used to minimize discomfort to the animals:
Route of
Type

Dosage

Administration

Anesthesia
Analgesia
Tranquilizer
Euthanasia CO2
B.

To affect

Inhalation

If no pain relieving measures are used, please justify:

C. If controlled substances will be used in the protocol, whose DEA and State of South
Dakota controlled substances registration will the agents be purchased and used under?
NA
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14.

Describe any additional approaches taken to minimize pain or discomfort, to control
infections, or otherwise insure the humane treatment of animals in this project. Also
describe how the animal care personnel will be trained.
Any animal suffering undue pain or distress will be humanely euthanized during the study
period. Animals will be maintained at the SPF level (autoclaved food and bedding,
acidified water). If signs of discomfort, injury or infections are observed, the veterinarian
will be consulted, and appropriate care will be provided and recorded. If the animals
develop untreatable diseases, the veterinarian will determine if euthanasia should be applied
before the ending of the study. All personnel are trained in how to handle mice in a way
that minimizes stress to the animals.

15.

If animals will be euthanized, describe the procedures to be used and method and site of
disposal. Unless a deviation is justified for scientific or medical reasons, methods should
be consistent with the most current version of the AMVA Guidelines on Euthanasia
(http://www.avma.org/issues/animal_welfare/euthanasia.pdf). If animals will not be
euthanized as part of the research project, describe their further use or plans for their
disposition; include euthanasia method for emergency situations.
All animals will be euthanized using CO2 at the ending of study or whenever required.
Blood of euthanized animals will be drawn via cardiac puncture. Biological specimens of
euthanized animals that die or euthanized will be harvested, snap-frozen in liquid nitrogen
and stored in a -80ºC freezer, and used for this study. The rest of the carcasses will be
incinerated.
NOTE: Animals are subject to post-mortem examination if unexplained death occurs
which is not a part of research protocol. Necropsy will be performed under the direction of
the attending veterinarian and/or the ADRDL. Laboratory confirmation will be provided
by the ADRDL. Researchers will be charged the standard fee for these services.

16.

Evaluate the effect on this project of using alternative procedures not including animals.
In vitro cell-culture models are not adequate to represent the entire process of gut microbial
interaction and ecology in health and diseased status. We cannot use conventional mice
model because they contain a vast variety of gut microbiota, which may potentially conflict
the outcomes. Hence, mice model with defined flora is the optimum model for our intent,
where we can control the confounding variables unlike in humans.

17.

Human health risks (Note: If this project is deemed to have significant human health risk,
it may be referred to the Institutional Biosafety Committee.)
A. What are the human health risks to which investigators and other contact personnel will
be subjected in working with animals in this project? Include physical, zoonotic, and
allergic risks.
Bites, scratches and allergies are potential human health risks for the personnel.
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B. What approach will be taken to minimize those risks, and how will laboratory and
animal care personnel be trained with regard to the risks?
The personnel on this project are trained in handling laboratory mice and in the procedures
taken in the protocol. The training and previous experience will minimize the above risks.
The mice will arrive here as SPF with defined flora and will be kept in strict SPF
environment. Personnel will wear gloves and lab coats while handling mice. These will
effectively prevent the potential human health risks.
18.

Personnel
A. Appropriate medical care for all animals will be available and provided as necessary by
a licensed and accredited veterinarian. Standard husbandry practices as defined in the
Guide for the Care and Use of Agricultural Animals in Research and Teaching Chapter
3 may be carried out by other trained individuals, as appropriate. Specify whether
veterinary care will be provided by the SDSU veterinarian or a consulting veterinarian
(provide the name of the individual involved with the project):
Dr. Michele Mucciante
(name of SDSU veterinarian or
consulting veterinarian) will provide the veterinary care and has been notified by me.
B. Education and Training Programs. Public Laws 99-158 and 99-198 require the
University to establish education and training programs to scientists and animal
technicians who handle and care for laboratory animals. Personnel must complete
training from the Collaborative Institutional Training Initiative (www.citiprogram.org)
read the appropriate SDSU training materials and/or view the appropriate tapes/CDs
and then sign a certification statement. Animal Usage Forms cannot be processed until
all persons handling and caring for the animals have signed certification statement on
file. Contact Janice Kampmann, ADR 106, phone 688-6649.
C. Additional training in specific techniques (restraint, anesthesia, euthanasia, injections,
etc.) are available through the University Veterinarian. The principal investigator's
signature on the bottom of this form is taken to indicate that training and education
requirements have been fulfilled.
D. List RESEARCH PERSONNEL who will have direct animal contact. Include their
position (principal investigator, graduate student, etc), their specific role in the project,
years of experience working with the species proposed to be used in the project, and
years of experience conducting the procedures they will be doing in the project.

Name

Position

Role in Project

Experience
(years) working
with the
proposed
species

Experience
(years)
with
procedures
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Moul Dey

Principal Investigator

Oversight of the entire project

9

9

Robert Juenemann

Graduate Student

Preparation of the reagents for 1
fecal transplantation, Animal
care

1

Collection
specimens

of

biological

CO2 euthanasia
Bijaya Upadhyaya

Graduate Student

Animal care, Blood collection 3
through
saphenous
vein,
Cardiac puncture, Collection of
biological specimens,

3

David Knudsen

Professor

Oversight of animal housing >20 years
and health, histopathology

>20 years

TBD

Undergraduate Student

Animal care and management

Will
trained

be

E. For research personnel that have not worked with animals before and/or have not
previously conducted the procedures described in this protocol, describe how training
for these individuals will be conducted.
19. ASSURANCE BY INVESTIGATOR:
I assure that these activities do not unnecessarily duplicate previous experiments conducted
here or elsewhere. I agree to conduct this project in accordance with applicable provisions
of the Animal Welfare Act, the Public Health Service (PHS) Policy on Humane Care and
Use of Laboratory Animals, the Guide for the Care and Use of Laboratory Animals, other
applicable federal laws, the laws of the State of South Dakota, and the policies of South
Dakota State University. All necessary State and Federal permits have been obtained, as
appropriate. I agree to conduct this project in accordance with the protocol submitted to the
Animal Care and Use Committee, to ensure that all research personnel are aware of and
follow the approved protocol, and to obtain prior approval from the committee before
modifying the protocol.
Signature of the Investigator

Date

*****************************
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Appendix 2: 3-Day Food Checklist
3-Day Food Checklist
Name:____________________________________
Date:_________________

ID:______________

Instructions





Fill out one Food Checklist throughout the day on the three days marked below:
 Sunday  Monday  Tuesday  Wednesday  Thursday  Friday  Saturday
Complete each Food Checklist by marking an ‘x’ in the box each time you ate a food on that day
(not what was available.
For example, if you drank a cup of milk at breakfast and one at lunch, you would mark 2 boxes. If
you had 2 slices of bread at breakfast and 2 at dinner you would mark 4 boxes.
If you had soup, be sure to mark it under the type of broth and also mark the vegetables or meat
that was in the soup.

Day 1
Mark how many servings of each of the following you ate.

Dairy – include flavored milks (serving = 1
liquid cup or 1 slice or oz for cheeses)

Milk – whole
Milk – 2%
Milk – 1% or skim
Margarine or butter (pat)
Yogurt, all kinds
Cheese, all kinds
Ice Cream or sherbert (1/2 c)









Beverages (serving = 1 cup)
Fruit juice (orange, grape, etc.)
Vegetable juice (tomato, etc.)
Wine or beer
Coffee
Tea
Pop, kool-aid, or punch
Pop, kool-aid, etc. DIET
Water










How many tsp of sugar do you put in your coffee
and/or tea? _____ teaspoons

Breads, Cereals & Grains
Bread, wheat (1 slice)
Bread, white (also biscuits, buns)
Noodles, dumplings (also
knödel, spätzel) (1/2 c)
Maultauschen, cottage
cheese pockets, etc. (1 item)
Oatmeal or oat cereal (1 c)
Rice or rice cereal (1 c)
Other grains (1 c)









Eggs, Fish, Poultry & Meat
(1 serving = 3 oz = 1 deck of cards)

Eggs (1)

Turkey or chicken

Sausage (include Thanksgiving sausage)      
Pork

Beef

Lunch meat (also chopped ham)

Did you eat the skin on your turkey or
chicken?
 No
 Yes  Sometimes, not
always

Fruits (serving=1 item or 1 cup)
Apples
Oranges
Banana
Melons
Other fruit







Vegetables (serving=1 item or 1/2 c)
Potatoes – fried (1 med)
Potatoes – baked (1 med)
Potatoes – boiled (1 med)
Lettuce
Tomatoes (1)
Beans, green (1/2 c)
Carrots, peas, corn
Beets
Squash
Cauliflower & broccoli
Cabbage (not sauerkraut)
Other vegetables














Sweets, Crackers, Pickles & Soups
Cake or cookies (2)
Pie (slice) (also kuchen&strudel)
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Candy (also chocolates, bars,



hard candy, etc.)

Crackers (2) (include saltines)
Pickled foods (1 Tblsp) (ex.




pickles, watermelon, tomatoes,
corn relish)

Sauerkraut
Soup – milk- based broth
Soup – clear broth





Thinking about the meat you had today.
About how many of these servings were
fried?
 All  Most  Some  None  Did not
have any
Did you eat anywhere not on the colony
today?
 Yes  No If yes,
describe__________________
Any other foods?
____________________________
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Day 2
Mark how many servings of each of the following you ate.

Dairy – include flavored milks (serving = 1

Fruits (serving=1 item or 1 cup)

liquid cup or 1 slice or oz for cheeses)

Apples
Oranges
Banana
Melons
Other fruit

Milk – whole
Milk – 2%
Milk – 1% or skim
Margarine or butter (pat)
Yogurt, all kinds
Cheese, all kinds
Ice Cream or sherbert (1/2 c)









Beverages (serving = 1 cup)
Fruit juice (orange, grape, etc.)
Vegetable juice (tomato, etc.)
Wine or beer
Coffee
Tea
Pop, kool-aid, or punch
Pop, kool-aid, etc. DIET
Water










How many tsp of sugar do you put in your coffee
and/or tea? _____ teaspoons

Vegetables (serving=1 item or 1/2 c)
Potatoes – fried (1 med)
Potatoes – baked (1 med)
Potatoes – boiled (1 med)
Lettuce
Tomatoes (1)
Beans, green (1/2 c)
Carrots, peas, corn
Beets
Squash
Cauliflower & broccoli
Cabbage (not sauerkraut)
Other vegetables














Sweets, Crackers, Pickles & Soups

Breads, Cereals & Grains
Bread, wheat (1 slice)
Bread, white (also biscuits, buns)
Noodles, dumplings (also
knödel, spätzel) (1/2 c)
Maultauschen, cottage
cheese pockets, etc. (1 item)
Oatmeal or oat cereal (1 c)
Rice or rice cereal (1 c)
Other grains (1 c)















Cake or cookies (2)
Pie (slice) (also kuchen&strudel)
Candy (also chocolates, bars,





hard candy, etc.)

Crackers (2) (include saltines)
Pickled foods (1 Tblsp) (ex.




pickles, watermelon, tomatoes,
corn relish)

Sauerkraut
Soup – milk- based broth
Soup – clear broth





Eggs, Fish, Poultry & Meat
(1 serving = 3 oz = 1 deck of cards)

Eggs (1)

Turkey or chicken

Sausage (include Thanksgiving sausage)      
Pork

Beef

Lunch meat (also chopped ham)

Did you eat the skin on your turkey or
chicken?
 No
 Yes  Sometimes, not
always

Thinking about the meat you had today.
About how many of these servings were
fried?
 All  Most  Some  None  Did not
have any
Did you eat anywhere not on the colony
today?
 Yes  No If yes,
describe__________________
Any other foods?
_____________________________
___________________________________
________
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Day 3
Mark how many servings of each of the following you ate.

Dairy – include flavored milks (serving = 1
liquid cup or 1 slice or oz for cheeses)

Milk – whole
Milk – 2%
Milk – 1% or skim
Margarine or butter (pat)
Yogurt, all kinds
Cheese, all kinds
Ice Cream or sherbert (1/2 c)









Beverages (serving = 1 cup)
Fruit juice (orange, grape, etc.)
Vegetable juice (tomato, etc.)
Wine or beer
Coffee
Tea
Pop, kool-aid, or punch
Pop, kool-aid, etc. DIET
Water










How many tsp of sugar do you put in your coffee
and/or tea? _____ teaspoons

Breads, Cereals & Grains
Bread, wheat (1 slice)
Bread, white (also biscuits, buns)
Noodles, dumplings (also
knödel, spätzel) (1/2 c)
Maultauschen, cottage
cheese pockets, etc. (1 item)
Oatmeal or oat cereal (1 c)
Rice or rice cereal (1 c)
Other grains (1 c)





Fruits (serving=1 item or 1 cup)
Apples
Oranges
Banana
Melons
Other fruit







Vegetables (serving=1 item or 1/2 c)
Potatoes – fried (1 med)
Potatoes – baked (1 med)
Potatoes – boiled (1 med)
Lettuce
Tomatoes (1)
Beans, green (1/2 c)
Carrots, peas, corn
Beets
Squash
Cauliflower & broccoli
Cabbage (not sauerkraut)
Other vegetables














Sweets, Crackers, Pickles & Soups
Cake or cookies (2)
Pie (slice) (also kuchen&strudel)
Candy (also chocolates, bars,





hard candy, etc.)






Eggs, Fish, Poultry & Meat

Crackers (2) (include saltines)
Pickled foods (1 Tblsp) (ex.




pickles, watermelon, tomatoes,
corn relish)

Sauerkraut
Soup – milk- based broth
Soup – clear broth





(1 serving = 3 oz = 1 deck of cards)

Eggs (1)
Turkey or chicken
Sausage (include Thanksgiving sausage)
Pork
Beef
Lunch meat (also chopped ham)








Did you eat the skin on your turkey or
chicken?
 No
 Yes  Sometimes, not
always

Thinking about the meat you had today.
About how many of these servings were
fried?
 All  Most  Some  None  Did not
have any
Did you eat anywhere not on the colony
today?
 Yes  No If yes,
describe__________________
Any other foods?
_____________________________
___________________________________
______
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